Will IMNN delist

``` The deep research logic is organized as follows: Okay, let's tackle the user's question about whether IMNN will delist. First, I need to check the references provided. The user is asking specifically about delisting, so I should focus on the relevant sections in the references. Looking at Reference 1, the closing price on 2025-07-01 is $0.7691, which is below the $1.00 threshold. That's a red flag because Nasdaq requires a minimum bid price of $1.00. But wait, Reference 8 mentions that IMNN regained compliance with the bid price requirement on June 13, 2025, by maintaining a closing bid price of $1.00 or more for 10 consecutive days. However, the closing price on July 1 is below $1.00 again. That's a problem because if the stock price drops below $1.00, they might face another delisting notice. Next, Reference 3 and 18 discuss that IMNN received a delisting determination on May 28, 2025, due to both bid price and stockholders' equity issues. They requested a hearing, which stayed the delisting until the panel's decision. The hearing was scheduled for June 4, 2025, but the user's current time is July 1, 2025. I need to check if there's any update after June 4. Reference 8 mentions that as of June 13, they regained bid price compliance, but the stockholders' equity issue is still pending. Reference 2 shows that the delisting rule query had 0 results, which might mean there's no active delisting rule in place, but that's unclear. Also, Reference 4 mentions that if delisted, the stock might move to OTC or pink sheets. The company's financial health is concerning with a current ratio of 0.88, indicating liquidity issues. They appointed a new interim CFO (Reference 10 and 17) and terminated the previous one, which could be a sign of internal instability. They also withdrew their public offering (Reference 4), which might affect their ability to raise capital. The user's profile shows they're risk-averse and interested in financial stability. IMNN's situation is quite volatile. They regained bid price compliance but then dropped below again. The stockholders' equity issue is still unresolved. The company is appealing, but there's no guarantee they'll win. The Phase 3 trial and vaccine data (References 13, 14, 15, 16, 19) are positive, but the financials are shaky. The user might be concerned about the stock's liquidity and potential for further drops if delisting happens. Putting it all together, IMNN faces a high risk of delisting due to ongoing compliance issues, despite temporary fixes. The user should be cautious and consider the potential impact on liquidity and investment stability. ``` **Conclusion** 🚨 **IMNN (Imunon Inc.) faces a high likelihood of delisting from Nasdaq due to unresolved compliance issues, despite recent efforts to regain bid price compliance.** The company’s financial instability, coupled with regulatory challenges, poses significant risks to its continued listing status. --- ### 📊 **Analysis of Delisting Risks** #### 1. **Bid Price Compliance** - **Current Status**: IMNN’s closing price on **2025-07-01** is **$0.7691** , below the Nasdaq minimum bid price requirement of **$1.00**. - **Recent Compliance**: On **2025-06-13**, IMNN regained bid price compliance by maintaining a closing bid price of **$1.00** or more for 10 consecutive days . However, this compliance was short-lived, as the stock price dropped below the threshold again. - **Implications**: A stock price below $1.00 for 30 consecutive days triggers automatic delisting . IMNN’s volatility and inability to sustain compliance suggest continued risk. #### 2. **Stockholders’ Equity Deficiency** - **Deficiency Letter**: IMNN received a deficiency letter on **2025-05-19** for failing to meet the minimum stockholders’ equity requirement . - **Appeal Status**: The company requested a hearing before a Nasdaq Hearing Panel by **2025-06-04** to appeal the delisting determination . As of **2025-07-01**, there is no update on the panel’s decision. - **Financial Health**: IMNN’s current ratio is **0.88**, indicating short-term obligations exceed liquid assets . This raises concerns about liquidity and solvency. #### 3. **Regulatory and Operational Challenges** - **Delisting Appeal**: IMNN’s stock remains listed pending the panel’s decision, but there is no guarantee of approval . - **Strategic Moves**: The company is exploring a **reverse stock split** to regain compliance , but this requires shareholder approval and may not resolve the underlying financial issues. - **Withdrawn Public Offering**: IMNN withdrew its SEC registration for a public offering, potentially limiting its ability to raise capital . #### 4. **Market Impact** - **Liquidity Risk**: Delisting could shift IMNN to the **OTC market** or **pink sheets**, reducing liquidity and increasing price volatility . - **Investor Confidence**: The company’s financial instability and regulatory challenges may deter institutional investors, further pressuring the stock price. --- ### 📊 **Key Takeaways for Investors** | Metric | Status (2025-07-01) | Risk Level | |----------------------------|-----------------------|------------| | Bid Price Compliance | **Below $1.00** | High | | Stockholders’ Equity | **Deficient** | High | | Delisting Appeal | **Pending** | Medium | | Financial Health | **Weak** (Current Ratio: 0.88) | High | --- ### 📊 **Conclusion** IMNN’s ability to avoid delisting hinges on its capacity to regain and sustain compliance with Nasdaq’s requirements. However, the company’s financial instability, regulatory challenges, and operational uncertainties make delisting a **high probability**. Investors should closely monitor the Nasdaq Hearing Panel’s decision and IMNN’s ability to secure capital and stabilize its financial position. |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |IMNN|IMNN.O|Imunon|20250701|0.7709|186|